Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat
A Multicenter, Double-blind, Placebo-controlled Safety Study of ATX-101 (Deoxycholic Acid) Injection for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects With Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) Grade 1 or CR-SMFRS Grade 4
Sponsor: Kythera Biopharmaceuticals
A PHASE3 clinical study on Efficacy and Moderate to Severe Convexity of Submental Fat, this trial is completed. The trial is conducted by Kythera Biopharmaceuticals and has accumulated 8 data snapshots since 2014. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Mar 2020 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jan 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kythera Biopharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Boca Raton, United States
- • Chestnut Hill, United States
- • Coral Gables, United States
- • Glenn Dale, United States
- • Newport Beach, United States
- • San Francisco, United States
- • St Louis, United States
- • West Hollywood, United States